$RAPH
Raphael Pharmaceutical Inc.

2023 Q2 Form 10-Q Financial Statement

#000121390023039833 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $144.0K
YoY Change
% of Gross Profit
Research & Development $293.0K $114.0K $86.00K
YoY Change 248.81% 32.56%
% of Gross Profit
Depreciation & Amortization $1.000K $0.00
YoY Change
% of Gross Profit
Operating Expenses $293.0K $114.0K $86.00K
YoY Change 248.81% 32.56%
Operating Profit -$419.0K -$258.0K -$175.0K
YoY Change -31.54% 47.43%
Interest Expense -$6.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.000K -$6.000K -$10.00K
YoY Change -113.33% -40.0%
Pretax Income -$264.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$417.0K -$264.0K -$185.0K
YoY Change -33.49% 42.7% -27.45%
Net Earnings / Revenue
Basic Earnings Per Share $0.03 $0.02 $0.01
Diluted Earnings Per Share $0.03 $0.02 $0.01
COMMON SHARES
Basic Shares Outstanding 16.08M shares 16.14M shares 13.04M shares
Diluted Shares Outstanding 16.11M shares 15.96M shares 13.04M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.00K
YoY Change
Cash & Equivalents $111.0K $38.00K $81.00K
Short-Term Investments
Other Short-Term Assets $7.000K $111.0K
YoY Change -88.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $118.0K $149.0K
YoY Change -39.8%
LONG-TERM ASSETS
Property, Plant & Equipment $1.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.000K $1.000K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $118.0K $149.0K
Total Long-Term Assets $1.000K $1.000K
Total Assets $119.0K $150.0K
YoY Change -39.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $147.0K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $12.00K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $180.0K $159.0K
YoY Change 130.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $180.0K $159.0K
Total Long-Term Liabilities $0.00
Total Liabilities $159.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$6.707M -$6.289M
YoY Change 92.79%
Common Stock $164.0K $160.0K
YoY Change 14.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$61.00K -$9.000K $103.0K
YoY Change
Total Liabilities & Shareholders Equity $119.0K $150.0K
YoY Change -39.29%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$417.0K -$264.0K -$185.0K
YoY Change -33.49% 42.7% -27.45%
Depreciation, Depletion And Amortization $1.000K $0.00
YoY Change
Cash From Operating Activities -$399.0K -$82.00K
YoY Change 386.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $149.0K $10.00K
YoY Change 1390.0%
NET CHANGE
Cash From Operating Activities -$399.0K -$82.00K
Cash From Investing Activities
Cash From Financing Activities $149.0K $10.00K
Net Change In Cash -$250.0K $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$399.0K -$82.00K
Capital Expenditures
Free Cash Flow -$399.0K -$82.00K
YoY Change 386.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-53002
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0204284
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4 Lui Paster Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv-Jaffa
CY2023Q1 dei Entity Address Country
EntityAddressCountry
IL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6803605
CY2023Q1 dei City Area Code
CityAreaCode
(+972)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
52-775-5072
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16084168 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
288000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
111000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
43000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
149000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
331000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000 usd
CY2023Q1 us-gaap Assets
Assets
150000 usd
CY2022Q4 us-gaap Assets
Assets
333000 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
147000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
224000 usd
CY2023Q1 cik0000141539 Due To Related Parties
DueToRelatedParties
12000 usd
CY2022Q4 cik0000141539 Due To Related Parties
DueToRelatedParties
3000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
159000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16002790 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16002790 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15624040 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15624040 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
160000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
157000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6120000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5974000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6289000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6025000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
150000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
333000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
144000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-258000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-175000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-264000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-185000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15964489 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13035371 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
149000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-264000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-9000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
128000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
160000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-185000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
103000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-264000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-185000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
68000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-170000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-68000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-67000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-399000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82000 usd
CY2023Q1 cik0000141539 Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
149000 usd
CY2022Q1 cik0000141539 Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
10000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
149000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-250000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-72000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
288000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81000 usd
CY2022Q1 us-gaap Stock Issued1
StockIssued1
150000 usd
CY2020Q4 cik0000141539 Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2020Q4 cik0000141539 Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-100
CY2021Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
9459253 shares
CY2021Q2 cik0000141539 Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2021Q2 us-gaap Shares Issued
SharesIssued
1051028 shares
CY2021Q2 cik0000141539 Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2023Q1 us-gaap Retained Earnings Unappropriated
RetainedEarningsUnappropriated
6289000 usd
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
255750 shares
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.13
CY2023Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
117000 usd
CY2023Q1 us-gaap Equity Method Investment Quoted Market Value
EquityMethodInvestmentQuotedMarketValue
250000 usd
CY2023Q1 cik0000141539 Company Raised Amount
CompanyRaisedAmount
25000 usd
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25000 shares
CY2023Q2 cik0000141539 Raised Amount
RaisedAmount
40000 usd
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Raphael Pharmaceutical Inc.
CY2023Q1 us-gaap Stock Issued1
StockIssued1
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001415397

Files In Submission

Name View Source Status
cik0000141539-20230331_cal.xml Edgar Link unprocessable
cik0000141539-20230331_lab.xml Edgar Link unprocessable
0001213900-23-039833-index-headers.html Edgar Link pending
0001213900-23-039833-index.html Edgar Link pending
0001213900-23-039833.txt Edgar Link pending
0001213900-23-039833-xbrl.zip Edgar Link pending
cik0000141539-20230331.xsd Edgar Link pending
f10q0323ex31-1_raphael.htm Edgar Link pending
f10q0323ex31-2_raphael.htm Edgar Link pending
f10q0323ex32-1_raphael.htm Edgar Link pending
f10q0323ex32-2_raphael.htm Edgar Link pending
f10q0323_raphaelpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
cik0000141539-20230331_def.xml Edgar Link unprocessable
cik0000141539-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0323_raphaelpharma_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending